BioCentury
ARTICLE | Clinical News

Smart M195 humanized antibody: Licensee Kanebo Ltd. (Osaka) began a Phase I trial in Japan to evaluate safety, pharmacokinetics, and potential efficacy in 16 pa

September 18, 1995 7:00 AM UTC

Protein Design Labs Inc. (PDLI), Mountain View, Calif. Product: Smart M195 humanized antibody Indication: Myeloid leukemia Status: Licensee Kanebo Ltd. (Osaka) began a Phase I trial in Japan to evalua...